# Improving assessment of prostate cancer bone metastases using advanced diffusion imaging

> **NIH NIH K08** · UNIVERSITY OF CALIFORNIA, SAN DIEGO · 2021 · $201,280

## Abstract

Project Summary
 Metastatic prostate cancer (PCa) is a debilitating and often deadly disease affecting tens of thousands
of men in the U.S. and worldwide. Effective therapeutic options exist for symptom relief and control of the
cancer, with others in the pipeline for testing. It is even thought that some patients might be cured if we could
detect metastatic disease when it is limited to only a small number of locations. However, both treatment and
testing of novel therapies require accurate imaging of the metastases. Unfortunately, most PCa metastases
are in bones, where imaging quality is poor, and metastases are considered unmeasurable with conventional
techniques. The broad goal of this project is to optimize and test innovative approaches to quantitative
imaging, radiation targeting, and response assessment of PCa. The proposal centers on distortion correction
and advanced diffusion MRI models, which are effective for detection of PCa lesions and have shown
promising association with clinical outcomes.
 The first specific aim of the proposal is to implement distortion-corrected diffusion MRI into a
radiotherapy treatment planning system and measure the impact of distortion correction on precise and
accurate tumor delineation in bone metastases. The second aim is to evaluate the prognostic value of diffusion
MRI metrics as predictors of clinical outcomes after radiotherapy for bone metastases, a treatment with
evidence of a survival benefit in some oligometastatic patients and important for quality of life in patients with
painful bone lesions. The third aim is to evaluate the reliability of diffusion MRI for quantitative treatment
response assessment of individual bone metastases, an unmet need for clinical practice and clinical trials.
 Dr. Seibert, assistant professor of Radiation Medicine and Bioengineering, seeks to advance patient
care with this proposal and to improve the ability of other investigators to more efficiently test experimental
treatments for PCa. Simultaneously, Dr. Seibert will gain mentored experience as a principal investigator and
build on his engineering, clinical, and imaging backgrounds with specific expertise in the development of
quantitative tools for PCa assessment. UC San Diego and the Center for Multimodal Imaging and Genetics—
directed by K08 proposal mentor, Dr. Dale—provide the ideal environment for this project and career
development, with a veteran team of mentors and an abundance of resources and skilled personnel to facilitate
successful completion of the specific aims and to launch Dr. Seibert’s career as a physician-scientist in
radiation oncology and biomedical imaging.

## Key facts

- **NIH application ID:** 10183247
- **Project number:** 5K08EB026503-03
- **Recipient organization:** UNIVERSITY OF CALIFORNIA, SAN DIEGO
- **Principal Investigator:** Tyler Michael Seibert
- **Activity code:** K08 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2021
- **Award amount:** $201,280
- **Award type:** 5
- **Project period:** 2019-07-01 → 2023-06-30

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/10183247

## Citation

> US National Institutes of Health, RePORTER application 10183247, Improving assessment of prostate cancer bone metastases using advanced diffusion imaging (5K08EB026503-03). Retrieved via AI Analytics 2026-05-23 from https://api.ai-analytics.org/grant/nih/10183247. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*